2026 ICD-10-CM Diagnosis Code T42.2X5AAdverse effect of succinimides and oxazolidinediones, initial encounter
T42.2X5A is a billable ICD-10-CM diagnosis code for adverse effect of succinimides and oxazolidinediones, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. Coders also document this condition as adverse reaction to oxazolidine derivative. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T42.2X5A.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction to oxazolidine derivative
- Adverse reaction to paramethadione
- Adverse reaction to phensuximide
- Adverse reaction to succinimide
- Adverse reaction to trimethadione
- Ethosuximide adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Ethosuximide
an anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.Trimethadione
an anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (from ama drug evaluations annual, 1994, p378)
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T42.2X5A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T42.2X5AOverview
Is T42.2X5A (Adverse effect of succinimides and oxazolidinediones) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of succinimides and oxazolidinediones, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T42.2X5A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of succinimides and oxazolidinediones, such as an emergency visit or first evaluation.
What MS-DRG does T42.2X5A group to?
On inpatient claims, adverse effect of succinimides and oxazolidinediones, initial encounter maps to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T42.2X5A be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of succinimides and oxazolidinediones, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What is the ICD-9 equivalent of T42.2X5A?
Under the General Equivalence Mappings, adverse effect of succinimides and oxazolidinediones, initial encounter converts to ICD-9-CM 995.29 (adv eff med/biol NEC/NOS), E936.2 (adv eff succinimides), and 995.29 (adv eff med/biol NEC/NOS). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
